73 results about "Behavioural disorders" patented technology

The present invention is a method for the treatment of eating disorders by nerve tissue stimulation and infusion techniques to one or more areas of the brain affecting hunger and satiety; palatability and aversion; hedonism; reward / addiction behavior; mood; anxiety; depression, taste and smell. The invention also comprises methods for the treatment of disorders of these individual behaviors and in particular, disorders of taste and / or smell.

The present invention describes a series of therapeutically active compounds of formula I,X—Y—Z  (I)that are useful for treating a disorder in a mammal. In the formula I, X and Z, which may be same or different, are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic group or substituted or unsubstituted heterocyclylalkyl; and Y is a linker selected from —O—, —S—, —NH—, —(CH2)n—, —CO—, —CONRa—, —NRaCO—, —NRaCOO—, —COO—, —CONRaCO—, —CONRaCOO— and —COOCOO—. The compounds are useful to treat neurodegenerative disorders, depression, Alzheimer's disease, cognitive disorders, motor disorders, Parkinson's disease, drug addiction, behavioral disorders, inflammatory disorders, stomach disorders, cancers, acute pain, chronic pain and recurrent pain.

The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. The compositions disclosed herein are further useful for treating platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy and the like.

The present invention relates to a method for treating a behavior disorder comprising the administration of a therapeutically effective amount of antihistamine, such as ceterizine, fexofenadine; loratadine, and desloratadine. The behavioral disorders may include ADHD, anxieity, depression, and autism. The method may include the administration of the antihistamine in combination with a stimulant medication, such as methylphenidate, thereby to achieve a synergistic effect. In any event, the amount of antihistamine and / or stimulant is effective to downregulate neurotrophic factors such as nerve growth factor or CD40. The invention is also directed to a method of preventing the onset of behavior disorders in patients presenting with symptoms of allergic rhinitis.

The present invention generally relates to the use of drugs for the treatment of neurobehavioral disorders or symptoms of a neurobehavioral disorder associated with dysfunction of the trimonoamine modulating system (TMMS). More specifically, the invention describes methods for the treatment of a neurobehavioral disorder and / or treatment or prevention of symptoms of a neurobehavioral disorder by administering suitable Isoindole derivatives alone or in combination with other agents so as to provide relatively equal inhibitory effect on serotonin, dopamine and norepinephrine transporters.

The present invention is directed to a method for the treatment of a patient suffering from psychiatric and behavioral disorders, including post partum depression, post traumatic stress disorder, compulsive smoking, attention deficit hyperactivity disorder, gambling addiction, comprising the step of administering a stellate ganglion block to the patient to alleviate the symptoms. The stellate ganglion block may be followed by a sympathectomy to provide permanent relief.

The invention provides a compound for use in the treatment of symptoms associated with psychosis, schizophrenia, a cognitive impairment disorder, a mood disorder, a nervous system disorder and / or a behavioral disorder. The compound has the formula ? and is administered to a subject in need thereof in an effective amount. The compound Meparfynol (3-methylpent-1-yn-3-ol) has been found to be effective.

The invention relates to the field of psychopharmacology. More particularly, the invention relates to the treatment of mental disorders, such as impaired interpersonal and behavioral disorders, including sexual disorders such as M.E.D. and H.S.D.D. The invention provides new therapeutic compositions and methods for treating mental disorders, including M.E.D. and H.S.D.D. The compositions and methods according to the invention provide improved awareness and alertness to environment, improved adaptation to environment and ability to sustain attention, and increased interest in environment and capacity for arousal, without increased aggressiveness.

The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioral disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention further-more relates to methods of altering expression of said receptors in vivo.

The present invention relates to certain pharmaceutical compositions of a 5-HT2A serotonin receptor modulator and methods for preparing pharmaceutical composition related thereto. The pharmaceutical compositions are useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.

The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

The invention discloses a rapid eye movement period sleep behavior disorder classification method based on sleep electroencephalogram. The method comprises the following steps: preprocessing an acquired sleep electroencephalogram signal of a patient, acquiring an electroencephalogram signal of an electroencephalogram interval in a sleep R period, cutting according to a preset signal length to acquire a plurality of sub-signal segments, layering an original electroencephalogram signal of each sub-signal segment, and enabling a frequency domain component after wavelet transform to approximatelycorrespond to different wave bands of original electroencephalogram according to the frequency of the electroencephalogram; carrying out empirical mode decomposition (EMD) to obtain a multilayer intrinsic mode function (IMF); performing feature extraction on the electroencephalogram signals of different wave bands and the multilayer intrinsic mode function, and performing dimensionality reductionon the feature set PCA to obtain a low-dimensional feature set; and carrying out classification and identification by using the feature set after dimension reduction, and classifying patients suffering from Parkinson's disease accompanied by rapid eye movement sleep disorder, Parkinson's disease not accompanied by rapid eye movement sleep disorder and idiopathic rapid eye movement period sleep behavior disorder. Complex PSG detection is simplified into electroencephalogram detection, a whole night does not need to be consumed, the number of times of measurement is reduced, an accurate recognition result is obtained, and then a very good auxiliary effect can be achieved on treatment of the illness state of a patient.

The present invention is one kind of red peony injection prepared with red peony root as material and through alcohol extraction, n-butanol extraction or macroporous resin purification, and adding proper amount of medicinal supplementary material and injection water. It is stable and may be used in intramuscular injection, intravenous injection and intravenous instillation. Pharmacodynamic experiment shows that the medicine of the present invention can improve the behavior disorder of rat with cerebral infarction obviously, reduce the area of cerebral infarction, decrease water content in infracted brain tissue, reduce the peroxidation damage of lipoid in brain tissue and raise the acute oxygen lack tolerance of mouse and thus has excellent treat effect on cerebral infarction.

The invention relates to a composition for use in the treatment of neurobehavioral disorders, a Cannabis plant extract comprising Cannabinol preferably with other constituents of this plant for such use and a method for the extraction of plants. The plants or plant parts may for instance be derived from Cannabis sativa and / or Cannabis indica and / or Cannabis ruderalis and / or citrus fruits, and mixtures thereof. The plant extracts derived showed particularly beneficial effects against sleeping disorders, in particular insomnia, and anxiety disorders including ADHD.

Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, ALS, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for evaluation in animal models of neurodegenerative diseases.

The present invention relates to the treatment of behavioral disorders, especially agitation, associated with a central nervous system (CNS) disorder, especially Alzheimer's disease (AD), cerebrovascular disease (VaD), or Down's Syndrome, in a mammal, comprising administering to said mammal an 1-aminocyclohexane, alone or in combination with a acetylcholinesterase inhibitor. In one embodiment, the 1-aminocyclohexane is memantine.

A system and method are provided for treating excessive or problematic computer use. In at least one embodiment, a method is employed to treat excessive or problematic computer use by acquiring information about the unwanted user activity, monitoring user activity for the unwanted behavior, controlling the behavior when it occurs, enabling the user to record self-observations and evaluating the results. This method may employ a computer based system to treat excessive or problematic computer use which includes configuring a user activity monitor with constraints, programmatically enforcing those constraints, reporting the activities monitored and restricted, and enabling a user to input self-observations. Potential constraints include a complete bar on the user activity, as well as, progressively decreasing the amount of time the user may engage in the activity, i.e. titrating the user activity.

The invention belongs to the technical field of medicine and discloses a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases. The pharmaceutical composition is prepared by ginsenoside and carithamine as main ingredients and can be prepared into pharmaceutically or clinically acceptable dosage forms. The pharmaceutical composition has functions of expanding blood vessels of brain, reducing cerebral vascular resistance, increasing cerebral blood flow, obviously minimizing infarct area of brain tissues, obviously lightening behavior disorders caused by brain tissue necrosis, and the like, and can be used for preparing medicaments for treating diseases such as cerebral circulation insufficiency, cerebral thrombosis, cerebral embolism, brain blood vessels spasm, brain insufficiency, senile dementia, Parkinsonism, cerebral apoplexy, hypertension, hyperlipemia, arteriosclerosis, coronary heart disease, angina pectoris, miocardial infarction, etc.

Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit / Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.

The present invention is directed to aryl sulfamide derivatives of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

A pharmaceutical composition containing the therapeutically active ingredients of azelastine or a pharmaceutically acceptable salt of azelastine and donepezil or rivastigmine or galantamine or a pharmaceutically acceptable salt of thereof is disclosed. A method of using the pharmaceutical composition for treating patients suffering from mental, behavioral, cognitive disorders is also disclosed.

The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.

The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioural disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention further-more relates to methods of altering expression of said receptors in vivo.

The invention relates to the field of medical treatment, and discloses a cognitive and behavioral disorder early warning method, device and equipment and a storage medium, and the method comprises the steps: obtaining the basic information of a detected object, inputting the basic information into a graph neural network, and obtaining a first prediction probability H1; receiving a biological signal uploaded by a monitoring bracelet of a measured object, and inputting the biological signal to the XGboost model to obtain a second prediction probability H2; receiving daily monitoring data uploaded by the monitoring bracelet, and inputting the daily monitoring data to the RNN model to obtain a third prediction probability H3; performing weighted calculation on the H1, the H2 and the H3 based on a preset weighting algorithm to obtain a disease probability H4 of the detected object; and if the H4 is higher than the preset probability threshold, generating an early warning signal, and sending the early warning signal to a preset port. Aiming at the technical problem that the disease and disease development of a patient cannot be monitored in real time at present, the method aims at finding the disease in advance, monitoring the specific physiological condition of the patient in real time in daily life, improving the diagnosis efficiency and realizing uninterrupted monitoring measures.

The present application describes methods for the testing of compounds of potential usefulness as therapeutic antioxidants and / or as therapeutic free radical scavengers. The animal model for testing such compounds is the Sod2CJE homozygous Manganese Superoxide Dismutase-deficient mouse. When pups of these mice are treated with certain antioxidants, they survive past about 7 days of age, and later develop characteristic histological changes and characteristic neurobehavioral disorders. Those treated mice can be further treated with test compounds which may or may not cross the blood brain barrier, and the life span and physical and neurobehavioral characteristics of those mice provide information about the potential utility of the test compound as a therapeutic antioxidant. Phenotypes of the treated mice allow conclusions regarding targeted areas of the brain and thus, applications to particular disorders such as Parkinsonism.

The invention discloses a probiotic composition for treating rapid eye movement sleep behavior disorder (RBD) in patients with Parkinson disease (PD). The composition is prepared from bacillus licheniformis, bifidobacterium longum, lactobacillus acidophilus, enterococcus faecalis and pharmaceutically acceptable auxiliary materials, wherein the number of live bacteria of the bacillus licheniformisis not less than 10.0x10<8> CFU / g; the number of live bacteria of the bifidobacterium longum is not less than 4.0x10<8> CFU / g; the number of live bacteria of the lactobacillus acidophilus is not lessthan 1.0x10<8> CFU / g; and the number of live bacteria of the enterococcus faecalis is not less than 0.5x10<8> CFU / g. In the probiotic composition, the components have a synergistic effect, the RBD symptom in the PD patients can be effectively treated and improved, and the treatment effect is good in continuity and excellent in stability; the composition can effectively improve the motor symptom ofthe PD patients while having a treatment effect on the RBD symptom of the PD patients, and solves the problem that current drugs cannot treat the motor symptom and non-motor symptoms of the PD patients at the same time; and the composition can effectively reduce the dosage of levodopa in the PD patients and prevent the patients from generating resistance to levodopa prematurely, and has a betterprotection effect on the patients.

The invention presented personalized biofeedback computerized system, an End-to-End eHealth smart platform for analysis, diagnosis and therapy of types of behavioral disorders. The system comprises a Captive Portal (CP) data input for initial input data and for continuous input data, a database comprising data, a Computer Processing Manager (CPM) for processing the patient data and the database, a Graphical User Interface (GUI) for interfacing with a user, and an Electroencephalography (EEG) or hemoencephalography (HEG) cap for stimulating predetermined areas in the brain, wherein the CPM is interconnected to the CPP, the database and the GUI, the CPM provides instructions for cranial electrode mediated stimulation to the areas in the brain according to a predetermined patient data dependent protocol, and the database provides external data. A preferred embodiment of the invention is a multilayered bio-feedbacking system.

The invention, belonging to the technical field of biology, relates to a protein-mediated brain-targeting gene delivery system and an application thereof, particularly an application in medicines for treating Parkinson disease. The gene delivery system is formed by modifying lactoferrin on a cationic high-molecular material through hydrophilic polymers to compound plasmid DNA by electrostatic action. According to the invention, the transfection efficiency and expression efficiency of genes on brain capillary vessel endothelial cells can be effectively improved, especially the brain targeting and the expression of the genes in the brain are significantly raised after administration through noninvasive intravenous injection; compared with a targeting head-constructed gene delivery system used in the prior art, the brain targeting effect is significantly improved. The results of the experiment of animal model prove that the gene delivery system can significantly improve the behavior disorder of animal pattern with Parkinson, obviously increase the number of dopaminergic neurons in corpus striatum and substantia nigra, and simultaneously raise the level of corpus striatum monoamine neurotransmitters.